Postmenopausal plasma sex hormone levels and breast cancer risk over 20 years of follow-up
- 826 Downloads
Plasma estrogen and androgen levels are positively associated with postmenopausal breast cancer risk, but how long a single blood measurement can predict risk and whether the associations vary by tumor hormone receptor status remain unclear. We conducted nested case–control analyses within the Nurses’ Health Study. Blood samples were collected in 1989–1990 and again in 2000–2002. Among postmenopausal women not using postmenopausal hormones at blood collection, 707 cases were diagnosed through June 2010, with two matched controls per case. We used unconditional logistic regression analyses to estimate the relative risks controlling for other breast cancer risk factors. The intra-class correlation coefficients for two blood measurements collected 10 years apart ranged from 0.54 (dehydroepiandrosterone sulfate, DHEAS) to 0.74 (sex hormone-binding globulin, SHBG). Overall, women in the top (vs. bottom) 25 % of levels of estradiol, free estradiol, testosterone, free testosterone, and DHEAS were at a 50–110 % higher risk of breast cancer (p trend < 0.001). SHBG was inversely associated with risk (p trend = 0.004). RRs were similar when comparing cases diagnosed 1–10 versus 11–20 years (or 16–20 years) after blood collection (p interaction > 0.2). Except for DHEAS, the associations varied significantly by hormone receptor status (p heterogeneity ≤ 0.02). For example, the RRs (95 % CIs) comparing the highest versus lowest quartile were 2.8 (2.0–4.0; p trend < 0.001) for ER +/PR + tumors versus 1.1 (0.6–2.1; p trend = 0.98) for ER−/PR− tumors for estradiol, and 1.8 (1.3–2.5; p trend < 0.001) versus 0.6 (0.3–1.2; p trend = 0.35) for testosterone. One measure of circulating sex hormones in postmenopausal women can predict risk of hormone receptor positive breast cancer for up to 16–20 years.
KeywordsBreast cancer Estrogens Androgens Hormone receptor
This work was supported by the National Institute of Health grants CA49449 and CA87969. We appreciate the participants and staff of the Nurses’ Health Study for their valuable contributions as well as the following state cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, WY.
Conflict of interest
The authors declare that they have no conflict of interest. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.
The experiments comply with the current laws of the country in which they were performed.
- 2.Key T, Appleby P, Barnes I, Reeves G, Endogenous Hormones, Breast Cancer Collaborative Group (2002) Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 94:606–616Google Scholar
- 5.Kaaks R, Rinaldi S, Key TJ, Berrino F, Peeters PHM, Biessy C, Dossus L, Lukanova A, Binghan S, Khaw KTG, Allen NE, Bueno-De-Mesquita HB, van Gils CH, Grobbee D, Boeing H, Lahmann PH, Nagel G, Chang-Claude J, Clavel-Chapelon F, Fournier A, Thiebaut A, Gonzalez CA, Quiros JR, Tormo MJ, Ardanaz E, Amiano P, Krogh V, Palli D, Panico S, Tumino R, Vineis P, Trichopoulou A, Kalapothaki V, Trichopoulos D, Ferrari P, Norat T, Saracci R, Riboli E (2005) Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocr Relat Cancer 12:1071–1082. doi: 10.1677/erc.1.01038 PubMedCrossRefGoogle Scholar
- 11.Tamimi RM, Colditz GA, Hazra A, Baer HJ, Hankinson SE, Rosner B, Marotti J, Connolly JL, Schnitt SJ, Collins LC (2012) Traditional breast cancer risk factors in relation to molecular subtypes of breast cancer. Breast Cancer Res Treat 131:159–167. doi: 10.1007/s10549-011-1702-0 PubMedCrossRefGoogle Scholar
- 13.James RE, Lukanova A, Dossus L, Becker S, Rinaldi S, Tjonneland A, Olsen A, Overvad K, Mesrine S, Engel P, Clavel-Chapelon F, Chang-Claude J, Vrieling A, Boeing H, Schutze M, Trichopoulou A, Lagiou P, Trichopoulos D, Palli D, Krogh V, Panico S, Tumino R, Sacerdote C, Rodriguez L, Buckland G, Sanchez MJ, Amiano P, Ardanaz E, Bueno-de-Mesquita B, Ros MM, van Gils CH, Peeters PH, Khaw KT, Wareham N, Key TJ, Allen NE, Romieu I, Siddiq A, Cox D, Riboli E, Kaaks R (2011) Postmenopausal serum sex steroids and risk of hormone receptor-positive and -negative breast cancer: a nested case-control study. Cancer Prev Res (Phila) 4:1626–1635. doi: 10.1158/1940-6207.CAPR-11-0090 CrossRefGoogle Scholar
- 14.Farhat GN, Cummings SR, Chlebowski RT, Parimi N, Cauley JA, Rohan TE, Huang AJ, Vitolins M, Hubbell FA, Manson JE, Cochrane BB, Lane DS, Lee JS (2011) Sex hormone levels and risks of estrogen receptor-negative and estrogen receptor-positive breast cancers. J Natl Cancer Inst 103:562–570. doi: 10.1093/jnci/djr031 PubMedCrossRefGoogle Scholar
- 16.Kahan Z, Gardi J, Nyari T, Foldesi I, Hajnal-Papp R, Ormandi K, Lazar G, Thurzo L, Schally AV (2006) Elevated levels of circulating insulin-like growth factor-1, IGF-binding globulin-3 and testosterone predict hormone-dependent breast cancer in postmenopausal women: a case-control study. Int J Oncol 29:193–200PubMedGoogle Scholar
- 17.Cummings SR, Lee JS, Lui LY, Stone K, Ljung BM, Cauleys JA, Osteoporotic Fractures Res G (2005) Sex hormones, risk factors, and risk of estrogen receptor-positive breast cancer in older women: a long-term prospective study. Cancer Epidemiol Biomarkers Prev 14:1047–1051. doi: 10.1158/1055-9965.epi-04-0375 PubMedCrossRefGoogle Scholar
- 18.Sieri S, Krogh V, Bolelli G, Abagnato CA, Grioni S, Pala V, Evangelista A, Allemani C, Micheli A, Tagliabue G, Schunemann HJ, Menard S, Berrino F, Muti P (2009) Sex hormone levels, breast cancer risk, and cancer receptor status in postmenopausal women: the ORDET Cohort. Cancer Epidemiol Biomarkers Prev 18:169–176. doi: 10.1158/1055-9965.epi-08-0808 PubMedCrossRefGoogle Scholar
- 19.Baglietto L, Severi G, English DR, Krishnan K, Hopper JL, McLean C, Morris HA, Tilley WD, Giles GG (2010) Circulating steroid hormone levels and risk of breast cancer for postmenopausal women. Cancer Epidemiol Biomarkers Prev 19:492–502. doi: 10.1158/1055-9965.epi-09-0532 PubMedCrossRefGoogle Scholar
- 20.Zeleniuchjacquotte A, Toniolo P, Levitz M, Shore RE, Koenig KL, Banerjee S, Strax P, Pasternack BS (1995) Endogenous estrogens and risk of breast cancer by estrogen receptor status: a prospective study in postmenopausal women. Cancer Epidemiol Biomarkers Prev 4:857–860Google Scholar
- 34.Dickson RB, Stancel GM (2000) Estrogen receptor-mediated processes in normal and cancer cells. J Natl Cancer Inst Monogr 135–145Google Scholar
- 35.Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 90:1371–1388. doi: 10.1093/jnci/90.18.1371 PubMedCrossRefGoogle Scholar
- 36.Kaufmann M, Bajetta E, Dirix LY, Fein LE, Jones SE, Zilembo N, Dugardyn JL, Nasurdi C, Mennel RG, Cervek J, Fowst C, Polli A, di Salle E, Arkhipov A, Piscitelli G, Miller LL, Massimini G (2000) Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol 18:1399–1411PubMedGoogle Scholar
- 38.Cuzick J, Forbes J, Edwards R, Baum M, Cawthorn S, Coates A, Hamed H, Howell A, Powles T, Clunie G, Collins R, Day N, Northover J, Investigators I (2002) First results from the International Breast Cancer Intervention Study (IBIS-1): a randomised prevention trial. Lancet 360:817–824PubMedCrossRefGoogle Scholar
- 40.Dimitrakakis C, Bondy C (2009) Androgens and the breast. Breast Cancer Res 11. doi: 10.1186/bcr2413
- 42.Zeleniuch-Jacquotte A, Shore RE, Koenig KL, Akhmedkhanov A, Afanasyeva Y, Kato I, Kim MY, Rinaldi S, Kaaks R, Toniolo P (2004) Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: long-term results of a prospective study. Br J Cancer 90:153–159. doi: 10.1038/sj.bjc.6601517 PubMedCrossRefGoogle Scholar
- 44.Castellano I, Allia E, Accortanzo V, Vandone AM, Chiusa L, Arisio R, Durando A, Donadio M, Bussolati G, Coates AS, Viale G, Sapino A (2010) Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers. Breast Cancer Res Treat 124:607–617. doi: 10.1007/s10549-010-0761-y PubMedCrossRefGoogle Scholar